Freeline To Participate In Conferences During January 2022
On January 4, 2022, Freeline Therapeutics Holdings plc (Nasdaq: FRLN) announced that CEO Michael Parini will present at two virtual conferences. The first is the H.C. Wainwright BioConnect Conference on January 10, 2022, with an on-demand webcast available at 7:00 a.m. EST. The second is the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, featuring a live audio webcast at 10:30 a.m. EST. Freeline specializes in AAV-mediated gene therapies for inherited diseases, with ongoing clinical programs in hemophilia B, Fabry disease, and Gaucher disease Type 1.
- None.
- None.
LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the "Company" or "Freeline"), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that Chief Executive Officer Michael Parini is scheduled to deliver a corporate presentation at both of the following virtual conferences:
- H.C. Wainwright BioConnect Conference, where an on-demand webcast will be available on January 10, 2022, starting at 7:00 a.m. EST.
- 40th Annual J.P. Morgan Healthcare Conference where a live audio webcast of the presentation will be available on January 13, 2022, at 10:30 a.m. EST.
The Company presentations will be available on the Investors section of the Company's website.
Senior management will participate in virtual one-on-one meetings with investors at both conferences as well as at the 11th Annual LifeSci Partners Corporate Access Event from January 5 to 7, 2022.
About Freeline Therapeutics
Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated systemic gene therapies. The Company is dedicated to improving patient lives through innovative, one-time treatments that provide functional cures for inherited systemic debilitating diseases. Freeline uses its proprietary, rationally designed AAV vector, along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into the patient’s bloodstream. The Company’s integrated gene therapy platform includes in-house capabilities in research, clinical development, manufacturing, and commercialization. The Company has clinical programs in hemophilia B, Fabry disease, and Gaucher disease Type 1. Freeline is headquartered in the UK and has operations in Germany and the US.
Contact
David S. Arrington
Vice President Investor Relations & Corporate Communications
Freeline Therapeutics
david.arrington@freeline.life
+1 (646) 668 6947
FAQ
What is Freeline Therapeutics scheduled to present at the H.C. Wainwright BioConnect Conference?
When will Freeline Therapeutics present at the J.P. Morgan Healthcare Conference?
What are the main clinical programs of Freeline Therapeutics?
Who is the CEO of Freeline Therapeutics?
Where can I find more information about Freeline Therapeutics presentations?
